Intellia Therapeutics (NTLA) plunges after patient death in pivotal CRISPR trial; Q3 update, analyst downgrades and what to watch next [Nov. 7, 2025]

7 November 2025

Intellia disclosed that a patient who suffered severe liver toxicity in its Phase 3 MAGNITUDE trial has died; FDA clinical holds on MAGNITUDE and MAGNITUDE‑2 remain in place. ^[1]
NTLA shares traded sharply lower intraday as Wall Street cut targets; RBC lowered its price target to $9 and flagged an unfavorable near‑term risk/benefit profile for the ATTR program. ^[2]
Q3 2025 results show $669.9M in cash and securities (runway into mid‑2027), with progress continuing in Intellia’s hereditary angioedema (HAE) program lonvoguran ziclumeran (lonvo‑z; NTLA‑2002). ^[3]

What happened today

Intellia Therapeutics (NASDAQ: NTLA) is under intense pressure after the company said the patient who experienced Grade 4 liver enzyme and bilirubin elevations in its Phase 3 MAGNITUDE study later died. In a Nov. 6 business update, CEO John Leonard said the treating physician cited “complicating comorbidities,” and Intellia is working with investigators and outside experts on a risk‑mitigation plan for nexiguran ziclumeran (nex‑z; NTLA‑2001), its in vivo CRISPR therapy for transthyretin amyloidosis (ATTR). The FDA’s clinical holds on MAGNITUDE (ATTR‑CM) and MAGNITUDE‑2 (ATTR‑PN) are still in effect pending a formal hold letter. ^[4]

Sell‑side reaction was swift. RBC Capital Markets cut its NTLA price target to $9 from $14, pointing to the patient death and the availability of alternative ATTR treatments as reasons to reassess the program’s risk/benefit trade‑off. Other firms also trimmed ratings and targets following the pause and hold. ^[5]

What the latest data say about the trials

Intellia paused dosing and screening on Oct. 27 after reporting the severe liver toxicity event in MAGNITUDE; two days later the FDA imposed clinical holds on both late‑stage ATTR trials. At the time of the pause, >650 patients had been enrolled across MAGNITUDE and MAGNITUDE‑2, with >450 estimated to have been dosed. Today’s company update reiterates that the team is investigating mechanisms and developing mitigation steps. ^[6]

What is nex‑z? It’s an in vivo CRISPR/Cas9 therapy intended to knock down the TTR gene in the liver after a single dose. Intellia leads development in collaboration with Regeneron. The company plans to present longer‑term Phase 1 data for ATTR‑CM at AHA 2025 on Nov. 10, which could offer additional context on durability and safety. ^[7]

Earnings snapshot: liquidity and operating runway

Alongside the clinical update, Intellia posted Q3 2025 results:

Cash, cash equivalents & marketable securities:$669.9M (vs. $861.7M at year‑end 2024), including $114.5M raised via ATM in Q3.
Collaboration revenue:$13.8M (Q3 2024: $9.1M).
R&D expense:$94.7M (Q3 2024: $123.4M).
Net loss:$101.3M or ($0.92) per share (Q3 2024: ($1.34)).
Management guides that its balance sheet funds operations into mid‑2027 and, if timelines hold, through the anticipated U.S. launch of its HAE program. ^[8]

HAE program remains the counterweight

While ATTR is in the spotlight, Intellia emphasized continued progress for lonvoguran ziclumeran (lonvo‑z; NTLA‑2002) in hereditary angioedema. The Phase 3 HAELO trial finished enrollment in September, with top‑line data expected by mid‑2026 and a potential BLA submission in 2H 2026. Longer‑term Phase 1/2 data in HAE will be presented Nov. 8 at ACAAI 2025. None of these timelines were changed in the company’s Q3 update. ^[9]

Street debate: platform risk or asset‑specific?

A core investor question is whether MAGNITUDE’s liver events reflect platform‑wide risk (CRISPR editing and delivery) or drug‑specific biology. Recent coverage noted company officials believe the signal may be tied to the gene target rather than Intellia’s delivery platform; still, with proven alternatives in ATTR, analysts caution that the bar for safety is high as regulators review the hold. ^[10]

Near‑term catalysts and watch‑outs

FDA clinical hold letter for MAGNITUDE and MAGNITUDE‑2: clarity on next steps and any required protocol changes. ^[11]
Scientific readouts: AHA (Nov. 10) for ATTR‑CM Phase 1 durability/safety; ACAAI (Nov. 8) for HAE longer‑term data. ^[12]
Sell‑side updates: Expect more revisions to ratings/targets as details emerge from FDA correspondence and upcoming presentations. ^[13]

Bottom line

Today’s headline for NTLA is the MAGNITUDE patient death and the ongoing FDA holds. That development – and the Street’s reaction – now dominates the near‑term setup. Intellia’s cash runway and advancing HAE program provide strategic optionality, but investors will likely reserve judgment until the hold letter arrives and the company outlines a credible risk‑mitigation path for nex‑z. ^[14]

This article is for information only and not investment advice.

Sources: Company press releases and filings; major financial and biotech news outlets cited throughout.

ESGCT e-Seminars: Intellia’s Modular CRISPR/Cas9 Gene Editing Platform for the Treatment of Disease

Watch this video on YouTube.

References

1. www.globenewswire.com, 2. www.investing.com, 3. www.globenewswire.com, 4. www.globenewswire.com, 5. www.investing.com, 6. www.globenewswire.com, 7. www.globenewswire.com, 8. www.globenewswire.com, 9. www.globenewswire.com, 10. www.barrons.com, 11. www.reuters.com, 12. www.globenewswire.com, 13. www.investing.com, 14. www.globenewswire.com

Tags:

Mateusz Kaczmarek Latest posts

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

View all

Chipotle Slumps 25% in a Month: Is the Selloff Creating a Buy Opportunity?
November 7, 2025, 12:34 PM EST. Chipotle Mexican Grill CMG has shed roughly 25% in the last month as investors weigh signs of slowing traffic among younger and lower-income diners. In the period, the broader market fared better-industry peers and the S&P 500 posted mixed to modest declines/gains. Management cited a 0.3% rise in third-quarter comparable sales, driven by a decline in transactions as households tighten budgets. The 25-35 age cohort remains a pressure point, and Chipotle's decision not to pursue aggressive menu-price hikes has kept sentiment cautious. Yet the company preserves core fundamentals, including strong new-unit economics, a resilient digital loyalty platform, and ongoing menu innovation. If transaction trends improve with operational and marketing initiatives, the pullback could verify a value opportunity for long-term investors, not a structural breakdown.
5 Dividend Growth Stocks to Weather Volatility: VRT, TPR, HCA, LRCX, CBOE
November 7, 2025, 12:32 PM EST. Amid a volatile market and tech-led sell-off, investors may favor dividend growth stocks over high-yield plays. Companies with a history of raising payouts often display strong financial health and can act as a defensive hedge. The piece spotlights Vertiv (VRT), Tapestry (TPR), HCA Healthcare (HCA), Lam Research (LRCX) and CBOE Global Markets (CBOE) as examples of durable dividend growth. Key filters include positive 5-year dividend growth, expanding sales and EPS, and Next 3-5 Year EPS Growth. Additional metrics look for Price/Cash Flow below industry peers and a 52-Week Price Change outperforming the S&P 500. Yields may be modest, but these firms offer upside potential and resilience in uncertain times.
Tilray Brands Soars 94.5% in 3 Months: Buy, Sell, or Hold?
November 7, 2025, 12:30 PM EST. Tilray Brands (TLRY) has jumped 94.5% over the last quarter, outpacing an industry that slipped about 2.5%. The rally followed a CNBC report on potential federal rules for hemp products and hints that a Trump administration could ease marijuana restrictions, plus Tilray's Q1 results showing record net revenues of $210 million and a strengthened balance sheet. The company is expanding its Tilray Medical footprint globally, including the Solana Life Group venture in Panama, new EU products from Germany, and a strategic Italy partnership with Molteni. In Australia, it launched its first medical cannabis edible. On the bottom line, Q1 net income rose to $1.5 million from a year-ago loss, with adjusted net income of $3.9 million as costs were disciplined. Zacks pegs 2026 sales up about 6.8%, with earnings guidance still evolving.
Consolidated Edison Q3 2025 Earnings Beat: Adjusted EPS $1.90, Revenues Rise 10.7% YoY
November 7, 2025, 12:28 PM EST. Consolidated Edison (ED) reported Q3 2025 adjusted EPS of $1.90, beating the Zacks Consensus by 7.9% and up 13.1% YoY, with GAAP EPS of $1.91. Total revenues reached $4.53 billion, topping estimates by 8.8% and rising 10.7% from the prior year. Segment highlights show electric revenues at $4.04 billion (+10%), gas at $433 million (+16.1%), and steam at $56 million (+14.3%); non-utility revenue was flat. Operating expenses climbed 10.2%, led by higher purchase power and fuel costs, while depreciation and taxes also rose. Operating income was $968 million (+12.3%). OCF for the first nine months: $3.11 billion. 2025 guidance narrowed to $5.60-$5.70 per share; Zacks Rank: #3 Hold.
Array Digital Infrastructure (AD) Q3 Earnings Beat Estimates; Revenue Tops Forecasts
November 7, 2025, 12:26 PM EST. Array Digital Infrastructure (AD) posted Q3 earnings of $0.97 per share, beating the Zacks Consensus Estimate of $0.25 and marking a 288% surprise. The year-ago figure was $0.26 per share. The quarterly results came with adjusted items. The company also delivered revenues of $47.12 million, topping the consensus by 2.10%. Year over year, revenue comparison was weak due to prior period anomalies (year-ago revenues listed as $922 million). Over the last four quarters, AD has surpassed EPS estimates three times and revenue estimates three times. The stock has fallen ~24% YTD, underperforming the S&P 500 (+14.3%). Ahead, estimates call for $0.24 EPS on $55.11 million revenues next quarter and $1.05 EPS on $1.91 billion in the current fiscal year. Zacks Rank: #3 Hold.